The blood cells, part of the body's first line of defense against infection, have been notoriously difficult to genetically engineer.
The findings, from a study by a UCLA-led team, could inform the development of precision antibiotics.
The shields can be mass-produced using laser cutting and 3D injection molding, giving quick relief to health workers battling the pandemic.
The development by a UCLA-led research team works to keep blood sugar at normal levels.
LL37 molecules, which are found in the immune system, play an important but unexpected role in revving up the body’s self-defense response.
In a lab test, half of the mice that received the treatment after having a tumor removed survived for at least 60 days without the tumor regrowing.
When injected into mice that had acute myeloid leukemia, the combination therapy halted the disease from developing any further.
The early work demonstrates the promise of so-called “mechanoceuticals."
A research team led by a UCLA bioengineer has created a model to predict the effectiveness of potential treatments to help the immune system.
The availability of such cells — with properties similar to those from humans and other animals — should help scientists accelerate research on therapies for cancer and autoimmune diseases.
“Tissues are wonderfully complex structures, so to engineer artificial versions of them that function properly, we have to recreate their complexity,” said UCLA professor Ali Khademhosseini.
The research explains concepts that were described nearly 90 years ago but had remained poorly understood until now.
UCLA research published in the journal Proceedings of the National Academy of Sciences is the first proof that a single material can be both static and moving.
The finding could eventually be used to help address human diseases associated with an imbalanced regulation of mitochondria size – for example, Alzheimer’s or Parkinson’s.
In a clinical trial, a UCLA-led team used a biomaterial embedded with tiny gems to help tissue heal after the procedure.
The injectable hydrogel works by forming a scaffold inside a wound that new tissue can grow around.
Sam Emaminejad, assistant professor of electrical engineering at UCLA, has demonstrated that a wearable biosensor can be used in the diagnosis of cystic fibrosis, diabetes and other diseases.
A UCLA team creates a "smart" mobile tool that may be used to diagnose and treat serious infections and diseases.
A simple and inexpensive attachment could help to expand testing to regions with limited resources.
The peptide discovery by UCLA researchers and others has broad implications for biomedicine.
UCLA biochemists have devised a way to convert sugar into a variety of useful chemical compounds without using cells and that could lead to the production of biofuels and pharmaceuticals.
The new technique can accurately identify a person’s optimal drug and dose combinations throughout an entire course of treatment, without complex, time-consuming genetic analysis.
Thyrosim can be used by clinicians, researchers and educators to gauge the impacts of thyroid treatments and to develop more effective remedies for thyroid problems.
Technique developed at UCLA automatically readjusts drug-dose combinations to zero in on the most effective ones.
New system can distinguish between subtly different cells so that only the correct, therapeutic cells are used for treatments.